XL 6q21/6q23

Deletion Probe

Order Number
Package Size
100 µl (10 Tests)
Regulatory Status

IVDR Certification

This probe is IVDR-certified in compliance with the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR).

MetaSystems Probes has already certified a large part of its portfolio, according to IVDR. For organizational reasons, we currently provide only the IVDD product.

Please use the switch to change to the IVDR product.

IVDDIVDRDiscover all IVDR-certified products

Product Description

XL 6q21/6q23

XL 6q21/6q23 consists of a green-labeled probe hybridizing to the SEC63 gene region at 6q21 and an orange-labeled probe hybridizing to the MYB gene region at 6q23.3.

Probe maps are created in accordance with the intended purpose of the product. Solid colored bars do not necessarily indicate that the probe fully covers the indicated genomic region. Therefore, caution is advised when interpreting results generated through off-label use. Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale. Further information is available on request.

Need assistance or a quote?

Clinical Details

The prognosis and clinical course of chronic lymphocytic leukemia (CLL) are heterogeneous. Conventional banding techniques in CLL are hampered by the low mitotic index of the neoplastic cells. The introduction of interphase cytogenetics using fluorescent in situ hybridization (FISH) has greatly increased the sensitivity of cytogenetic analyses. With FISH, abnormalities can be detected in more than 80% of patients by using a 4-probe panel for the detection of trisomy 12q13-15 and deletions 13q14, 17p13, and 11q22-23. An additional 10% of patients can be shown to carry a 6q21 deletion, 14q32 translocation, and partial trisomy 3q or 8q.

Deletions involving the long arm of chromosome 6 (6q) are among the most common structural aberrations leading to a loss of chromosomal material in lymphoproliferative disorders and non-Hodgkin lymphoma (NHL). Two distinct regions, one at 6q21-22.1, the other at 6q23.3-25, have been found as minimal deleted regions in 6q- patients. A 6q deletion has also been found in a variety of other human malignancies, including breast carcinoma, malignant melanoma, renal cell carcinoma, salivary gland adenocarcinoma, ovarian carcinoma, acute lymphoblastic leukemia, and nodal non-Hodgkin lymphomas.

Clinical Applications

  • Acute Lymphoblastic Leukemia (ALL)
  • Chronic Lymphocytic Leukemia (CLL)
  • Non-Hodgkin Lymphomas (NHL)
Need assistance or a quote?


XL 6q21/6q23

XL 6q21/6q23 hybridized to lymphocytes. One normal interphase and metaphase are shown.

Need assistance or a quote?

Expected Patterns

Expected Pattern 1

Normal Cell:
Two green (2G) and two orange (2O) signals.

Expected Pattern 2

Aberrant Cell (typical results):
Two green (2G) and one orange (1O) signal resulting from loss of one orange signal.

Expected Pattern 3

Aberrant Cell (typical results):
One green (1G) and two orange (2O) signal resulting from loss of one green signal.

Expected Pattern 4

Aberrant Cell (typical results):
One green (1G) and one orange (1O) signal resulting from loss of one green and one orange signal.

Need assistance or a quote?


  • Stilgenbauer et al (1999) Leukemia 13:1331-1334
  • Zhang et al (2000) Genes Chrom Canc 27:52-58
  • Starostik et al (2000) Blood 95:1180-1187



IVDR Certification

MetaSystems Probes has received IVDR certification for our initial 26 fluorescence in situ hybridization (FISH) probes from the notified body, BSI. Achieving this milestone was not without its challenges, and we are delighted to have accomplished IVDR certification for this probe set at an early stage.

IVDR Certification